Michael Bär

2.6k total citations
20 papers, 246 citations indexed

About

Michael Bär is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Michael Bär has authored 20 papers receiving a total of 246 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Michael Bär's work include Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (3 papers) and Peptidase Inhibition and Analysis (3 papers). Michael Bär is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (3 papers) and Peptidase Inhibition and Analysis (3 papers). Michael Bär collaborates with scholars based in United States, Canada and Germany. Michael Bär's co-authors include Hal S. Wasserman, Andrew J. Dwork, Margaret M. Grimes, Dhanpat Jain, Philip Stein, Sarah M. Lo, Gregory M. Pastores, Pramod K. Mistry, Axel Meye and Michael J. Meurer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Investigative Dermatology.

In The Last Decade

Michael Bär

19 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Bär United States 8 87 66 54 48 48 20 246
Stephan Fuhrmann Germany 11 120 1.4× 110 1.7× 115 2.1× 38 0.8× 134 2.8× 18 398
G. Ghigliotti Italy 11 73 0.8× 72 1.1× 38 0.7× 35 0.7× 27 0.6× 25 242
Rick TH Ong Singapore 4 82 0.9× 24 0.4× 83 1.5× 22 0.5× 27 0.6× 5 403
Satoko Oka Japan 10 25 0.3× 69 1.0× 61 1.1× 47 1.0× 67 1.4× 59 297
Nobuya Hiraoka Japan 9 32 0.4× 74 1.1× 78 1.4× 72 1.5× 43 0.9× 22 254
Kenshiro Tsuda Japan 9 46 0.5× 29 0.4× 51 0.9× 29 0.6× 35 0.7× 14 266
R André Switzerland 8 29 0.3× 43 0.7× 30 0.6× 29 0.6× 63 1.3× 63 260
Tomoo Osumi Japan 11 54 0.6× 104 1.6× 110 2.0× 83 1.7× 90 1.9× 54 374
Aya Nishizawa Japan 11 41 0.5× 80 1.2× 59 1.1× 33 0.7× 24 0.5× 35 255
Masahiro Yasui Japan 12 47 0.5× 145 2.2× 72 1.3× 58 1.2× 86 1.8× 40 404

Countries citing papers authored by Michael Bär

Since Specialization
Citations

This map shows the geographic impact of Michael Bär's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bär with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bär more than expected).

Fields of papers citing papers by Michael Bär

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bär. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bär. The network helps show where Michael Bär may publish in the future.

Co-authorship network of co-authors of Michael Bär

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Bär. A scholar is included among the top collaborators of Michael Bär based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Bär. Michael Bär is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2024). Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014. Clinical Lymphoma Myeloma & Leukemia. 24(12). 852–862. 2 indexed citations
2.
Bär, Michael, et al.. (2024). The evaluation of therapeutic outcomes of biologics in allergic fungal rhinosinusitis: a systematic review and meta-analysis. Rhinology Journal. 0(0). 0–0. 2 indexed citations
3.
Bär, Michael, et al.. (2023). Invariance principles for integrated random walks conditioned to stay positive. The Annals of Applied Probability. 33(1). 1 indexed citations
4.
Bahlis, Nizar J., Gary J. Schiller, Christy Samaras, et al.. (2022). P-232: Adverse event patterns and management with pomalidomide, dexamethasone, and daratumumab in patients with relapsed or refractory multiple myeloma: a safety analysis of the phase 2 MM-014 study. Clinical Lymphoma Myeloma & Leukemia. 22. S162–S163. 1 indexed citations
5.
6.
Siegel, David S., Gary J. Schiller, Christy Samaras, et al.. (2020). Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial. Blood. 136(Supplement 1). 16–17. 3 indexed citations
7.
Siegel, David S., Gary J. Schiller, Christy Samaras, et al.. (2018). Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure. Blood. 132(Supplement 1). 3271–3271. 5 indexed citations
8.
Siegel, David S., Gary J. Schiller, Christy Samaras, et al.. (2018). Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.. Journal of Clinical Oncology. 36(15_suppl). 8027–8027.
9.
Bär, Michael, et al.. (2013). A case of seronegative catastrophic antiphospholipid antibody syndrome.. PubMed. 77(2). 81–3. 6 indexed citations
10.
Bär, Michael. (2012). Spitz and Reed nevi: acquired or congenital?. Dermatology Practical & Conceptual. 2(3). 21–27. 3 indexed citations
11.
Bär, Michael, Philipp Tschandl, & Harald Kittler. (2012). Differentiation of pigmented Spitz nevi and Reed nevi by integration of dermatopathologic and dermatoscopic findings. Dermatology Practical & Conceptual. 2(1). 13–24. 13 indexed citations
12.
Bär, Michael, et al.. (2011). Cutaneous and uterine leiomyomatosis and ovarian cystadenoma associated with deficiency of fumerate hydratase. Dermatology Practical & Conceptual. 1(1). 25–27. 1 indexed citations
13.
Richardson, Paul G., Jeffrey L. Wolf, Andrzej Jakubowiak, et al.. (2011). Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. Blood. 118(21). 815–815. 1 indexed citations
14.
Lo, Sarah M., Philip Stein, Michael Bär, et al.. (2010). Expanding spectrum of the association between Type 1 Gaucher disease and cancers: A series of patients with up to 3 sequential cancers of multiple types—Correlation with genotype and phenotype. American Journal of Hematology. 85(5). 340–345. 36 indexed citations
15.
16.
Bär, Michael, et al.. (2006). Wavelength-Dependent Induction of CYP24A1-mRNA after UVB-Triggered Calcitriol Synthesis in Cultured Human Keratinocytes. Journal of Investigative Dermatology. 127(1). 206–213. 22 indexed citations
17.
Savage, David G., Charles S. Hesdorffer, Daniel F. Heitjan, et al.. (2003). Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia. Leukemia & lymphoma. 44(3). 477–481. 24 indexed citations
18.
Amato, Joseph J., et al.. (1998). Psychological support to an autologous bone marrow transplant unit in a community hospital: a pilot experience. Psycho-Oncology. 7(2). 121–125. 6 indexed citations
19.
Margolin, Kim, Frederick R. Aronson, Mario Sznol, et al.. (1991). Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin??s Disease and Non-Hodgkin??s Lymphom. Journal of Immunotherapy. 10(3). 214–220. 21 indexed citations
20.
Grimes, Margaret M., et al.. (1987). Disseminated Pneumocystis carinii infection in a patient with acquired immunodeficiency syndrome. Human Pathology. 18(3). 307–308. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephan Fuhrmann Breakdown of academic impact, for papers by G. Ghigliotti Breakdown of academic impact, for papers by Rick TH Ong Breakdown of academic impact, for papers by Satoko Oka Breakdown of academic impact, for papers by Nobuya Hiraoka Breakdown of academic impact, for papers by Kenshiro Tsuda Breakdown of academic impact, for papers by R André Breakdown of academic impact, for papers by Tomoo Osumi Breakdown of academic impact, for papers by Aya Nishizawa Breakdown of academic impact, for papers by Masahiro Yasui
Rankless by CCL
2026